

# Differential imaging: what for which patient?

Jeroen J Bax

Dept of Cardiology

Leiden Univ Medical Center

The Netherlands

Davos, feb 2013

Research grants: Medtronic, Biotronik, Boston Scientific,  
St Jude, BMS imaging, GE Healthcare, Edwards  
Lifescience

# Coronary Atherosclerosis

```
graph TD; A[Coronary Atherosclerosis] --> B["Coronary Narrowing"]; A --> C["Vulnerable Plaque"]; B --> D["Transient Ischemia<br/>Angina - Infarction"]; C --> E["Myocardial Infarction<br/>Sudden Death"];
```

**“Coronary Narrowing”**

**“Vulnerable Plaque”**

**Transient Ischemia  
Angina - Infarction**

**Myocardial Infarction  
Sudden Death**


**“Severity”**

**“Vulnerability”**

# Ischemia – Severity

How to evaluate  
non-invasively?


# Diagnosis of ischemia - the ischemic cascade




# Ischemia as an expression of a flow-limiting stenosis

- **Assessment of**
  - perfusion abnormalities (stress-inducible)
- **Assessment of**
  - systolic wall motion abnormalities (stress-inducible)

# Nuclear perfusion imaging, SPECT




POLAR MAP TO QUANTIFY  
EXTENT AND SEVERITY OF ISCHEMIA




# Nuclear perfusion imaging with ECG gating


- Permits assessment of LVEF, LV volumes and regional function
- At rest and stress



# Resolution of SPECT vs PET



**SPECT**



**PET**

# Diagnostic accuracy SPECT vs PET


percentage

100


80

60

40



87



73

sens


spec

3425 pts

Underwood et al. EJNM 2004



90



89

sens

spec


1660 pts

Beanlands et al. JNC 2010

# Stress echo to assess flow-limiting stenosis: wall motion

rest

10 mcg



40

rest

# Stress echo to detect CAD

## hall mark: WMA


percentage

100


80

60

40



sens




spec

28 studies  
2246 pts

# Addition on intravenous contrast to improve border opacification







LOCAL: Longitudinal Strain (%) = -5.81

T=1114 msec



Quantification using  
strain or strain rate imaging



# Stress MRI to assess flow-limiting stenosis: wall motion



# MRI – perfusion imaging



# Stress MRI to assess flow-limiting stenosis: perfusion vs wall motion

percentage

100

80


60

40




**sens**

**15 studies  
355 pts**




**spec**



**sens**

**12 studies  
704 pts**



**spec**


# **Comparison of imaging techniques for assessment of ischemia**

- **all modern techniques**
  - **can assess perfusion**
  - **and systolic function**
- 
- **perfusion may be more sensitive**
  - **to assess ischemia**
  - **than systolic function**


# Plaque – Vulnerability?

How to evaluate  
non-invasively?


# MRI – angiography (1.5T)




Leiden, NL




Aarhus, DK




Munich, GER



Boston, USA




Berlin, GER



Leeds, UK



Kurashiki, JP



St. Louis, USA

# MRI to detect CAD


percentage

100

80

60

40




23 studies  
761 pts

Schuijf et al. AHJ 2006




Multi-center trial 2010  
7 hosp, 138 pts

Kato et al. JACC 2010

# MRI - angiography



Stronger magnets:  
3T coronary imaging






Yang et al. JACC 2009


# CT angiography - raw data




# curved MPR



**RCA**




**LAD**



**LCX**

# Meta-analysis 64-slice CT

Patient-based detection (n=1286)






# Technical developments

- **Dual-source CT: higher temporal resolution**
- **Prospective gating: lower radiation**
- **256- and 320-slice CT**


# Accuracy dual-source CT

24 studies, 801 pts  
gold standard  $\geq 50\%$  stenosis on angiography



# 320-CT


## Coverage of the heart in 1 rotation



16 cm

# Meta-analysis 64-slice CT

Patient-based detection (n=1286)



Rule out  
CAD

# Patient example

Man 47 years old


Outpatient clinics:

Dyspnea or atypical chest pain at exercise


Risk factors for CAD:

\*Dyslipidemia

# Non-invasive angiography - MSCT



LAD: normal,  
intramural course mid





LCx: normal

# 320-CT – rule out CAD

57 yr old woman, 2x TIA

Analysis cardiac source of embolism



# 320-CT – rule out CAD


Smoking 39 pack years

Severe dyslipidemia (chol 7.8 mmol/L)

MSCT angiography to exclude (?) CAD



LAD





LCx



RCA


No significant stenosis

# 320-CT



# MSCT coronary angiography for actual rule out of CAD

*N=340*



***No CAD: 40%***


*Non-obstructive CAD: 34%*

*Obstructive CAD: 21%*


*Uninterpretable: 5%*

# Prognosis MSCT

13,966 pts, mean F-up 22.5 months



**If there is atherosclerosis,  
then which of these lesions  
is vulnerable?**



# EXAMPLE

- Male, 45 years, no cardiac history
- Presented at ED with acute chest pain

## **Risk factors for CAD:**

- Hypertension and positive family history

## **LAB and ECG:**

- ECG: no ST elevation, no Q waves
- Troponin borderline elevated

ACS?



# MSCT calcium



**CALCIUM = 0**



**No significant CAD?**

# MSCT coronary angiography




<50% stenosis LAD  
(non-calcified)


# MSCT coronary angiography



# Fusion between anatomic and functional imaging: PET/SPECT-CT



**CT Angiography**




**PET/SPECT  
Using Plaque-  
Targeted Tracer**




**Fusion**

# Fusion of anatomic and functional imaging (PET-CT) - carotid arteries


Unstable  
(recent TIA)



Stable



# Plaque inflammation on FDG PET - CTA



Coregistered FDG-PET and CTA images demonstrating increased FDG uptake in LAD plaques stented for ACS

# Assessing vulnerable plaque:

- What are the characteristics?
- Which imaging technology?
- When to assess?
- Do we need to assess periodically?
- Will it improve outcome?
- What are the therapeutic consequences?